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HIV-1 replication is induced by an excess of iron and iron chelation by desferrioxamine (DFO) inhibits viral replication by reducing
proliferation of infected cells. Treatment of cells with DFO and 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311) inhibit expression of
proteins that regulate cell-cycle progression, including cycle-dependent kinase 2 (CDK2). Our recent studies showed that CDK2 participates in
HIV-1 transcription and viral replication suggesting that inhibition of CDK2 by iron chelators might also affect HIV-1 transcription. Here we
evaluated the effect of a clinically approved orally effective iron chelator, 4-[3,5-bis-(hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid (ICL670)
and 311 on HIV-1 transcription. Both ICL670 and 311 inhibited Tat-induced HIV-1 transcription in CEM-T cells, 293T and HeLa cells. Neither
ICL670 nor 311 induced cytotoxicity at concentrations that inhibited HIV-1 transcription. The chelators decreased cellular activity of CDK2 and
reduced HIV-1 Tat phosphorylation by CDK2. Neither ICL670A or 311 decreased CDK9 protein level but significantly reduced association of
CDK9 with cyclin T1 and reduced phosphorylation of Ser-2 residues of RNA polymerase II C-terminal domain. In conclusion, our findings add to
the evidence that iron chelators can inhibit HIV-1 transcription by deregulating CDK2 and CDK9. Further consideration should be given to the
development of iron chelators for future anti-retroviral therapeutics.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Iron; Iron chelation; Desferrioxamine (DFO); 2-Hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311); 4-[3,5-bis-(hydroxyphenyl)-1,2,4-
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Increased iron stores correlate with faster HIV-1 progression in
HIV-1 positive thalassemia major patients, in HIV-positive patients
who were administered oral iron and in HIV-positive subjects with
haptoglobin 2–2 polymorphism associated with higher iron stores
(Gordeuk et al., 2001). Moreover, a retrospective study of bone
marrow macrophage iron in HIV-positive patients suggested that
survival is shorter with higher iron stores (reviewed in Gordeuk et
al., 2001). In cultured Tcells, excess of iron stimulated HIV-1 viral⁎ Corresponding author. Center for Sickle Cell Disease, 1840 7th Street, N.W.
HURB1, Suite 202, Washington, DC 20001, USA.
E-mail address: snekhai@howard.edu (S. Nekhai).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.06.011replication, whereas iron chelation with desferrioxamine (DFO)
lowered viral replication as measured by decreased p24 levels and
reverse transcriptase (RT) activity (Traore and Meyer, 2004).
Treatment of monocyte-derived macrophages and peripheral blood
lymphocytes (PBL) with DFO or deferiprone (CP20) reduced
expression of p24 and also cellular proliferation (Georgiou et al.,
2000). The orally active bidentate chelators CP502 and CP511
decreased HIV-1 replication and cellular proliferation in a manner
similar to DFO and CP20 (Georgiou et al., 2002). Reduction of
HIV-1 replication by DFO or by hydroxypyridinone bidentate
chelators may be through inhibition of cellular proliferation rather
than by a direct antiviral action. Recently, a new oral tridentate iron
chelator, Deferasirox (ICL670), was introduced by Novartis
(Porter, 2006). ICL670A may be potentially more effective than
325Z. Debebe et al. / Virology 367 (2007) 324–333the previously usedDFOand deferiprone and is approved for use in
the United States (Porter, 2006). Thus, it would be of interest to test
the effect of ICL670 on HIV-1. Latent HIV-1 provirus is activated
by viral Tat protein that recruits cellular factors to the HIV
promoter. Tat interacts with the protein kinases CDK9/cyclin T1
and CDK2/cyclin E, with the acetyltransferases p300/CBP, PCAF
and hGCN5, with protein phosphatase-1 and other factors
(Nekhai and Jeang, 2006). We previously reported that CDK2
is required for Tat-dependent transcription in vitro (Ammosova et
al., 2006, 2005a; Deng et al., 2002; Nekhai et al., 2002) and that
inhibition of CDK2 by CYC202 (R-roscovitine) (Agbottah et al.,
2005) or by siRNA (Ammosova et al., 2005a) efficiently blocks
replication of HIV-1. Moreover, Tat is phosphorylated by CDK2
in cultured cells and inhibition of this phosphorylation by mu-
tation of Ser16 and Ser46 residues of Tat blocked HIV-1
transcription and viral replication (Ammosova et al., 2006).Fig. 1. Iron chelators 311 and ICL670 inhibit Tat-induced HIV-1 transcription in CEM
indicated amounts of Ad-Tat or Ad-LacZ. At 24 h the cells were lysed and GFP fluores
in 96-well plate were infected with 100 Pfu/cell of Ad-Tat and treated with the indicat
photographs were taken. (c) CEM-GFP cells were grown in 96-well plates, infected
and ICl670. At 24 h the cells were lysed and GFP fluorescence was measured on aRichardson and colleagues showed that the iron chelator 2-
hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311)
inhibited the expression of CDK2 (Gao and Richardson, 2001).
Thus, of iron chelators could conceivably affect the activity of
CDK2 and thereby inhibit HIV-1 transcription and viral replication.
In the present study, we analyzed the effect of the iron
chelators, ICL670 and 311, on HIV-1 transcription and on the
expression and activities of CDK2 and CDK9 in cultured cells.
Results
Iron chelators 311 and ICL670 inhibit Tat-induced HIV-1
transcription in CEM T-cells and 293T cells
We examined the effect of iron chelators 311 and ICL670 (see
their structure in Supplemental Fig. 1) on HIV-1 transcription inT-cells. (a) CEM-GFP T-cells were grown in 96-well plate and infected with the
cence was measured on a luminescence spectrometer. (b) CEM-GFP cells grown
ed concentrations of 311 and ICL670. Cell cultures were continued for 24 h, and
with 100 Pfu/cell of Ad-Tat and treated with the indicated concentrations of 311
luminescence spectrometer.
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GFP). We infected CEM-GFP cells with adenovirus expres-
sing Tat (Ad-Tat) (Ammosova et al., 2003; Nekhai et al., 2007a).
In CEM-GFP cells HIV-1 transcription was detectable after
infection with Ad-Tat but not with non-relevant Ad-LacZ virus
(Fig. 1a). Treatment of the Ad-Tat infected CEM-GFP cells with
either ICL670 (100 μM) or 311 (10 μM) resulted in inhibition of
Tat-mediated HIV-1 transactivation as visualized by fluores-
cence (Fig. 1b). Titration of the iron chelators showed that
ICL670 inhibited HIV-1 transcription in CEM-GFP cells with an
IC50=23 μM(Fig. 1c) and that 311 inhibited HIV-1 transcription
with an IC50=2 μM (Fig. 1c). To determine whether the effect of
the iron chelators might be due to reduced expression of Tat, we
induced Tat-transactivation with purified recombinant Tat
protein added to the media in the presence of chloroquine
(Frankel and Pabo, 1988). Recombinant Tat potently induced
HIV-1 transcription in CEM-GFP cells (Fig. 2a, lane 2).Fig. 2. (a) Iron chelators inhibit HIV-1 transcription induced by extracellular Tat.
CEM-GFP cells were placed in 96-well plates, supplemented with recombinant
Tat (3 μg/300,000 cells) and 100 μM chloroquine and treated with the indicated
concentrations of ICL670 or 311. Cell cultures were continued for 24 h. The
cells were lysed and GFP fluorescence was measured on a Luminescence
Spectrometer. (b) Iron chelators inhibit HIV-1 transcription from pNL4-3.Luc.
293T cells were grown in 96-well plates and transfected with pNL4-3.Luc.R-E-
construct (lane 1) and treated with the indicated concentrations of ICL670 or 311
(lanes 2 and 3). Lane 4, mock transfected cells. At 48 h posttransfection, the cells
were lysed using Luclite luminescence reporter buffer containing luciferase
substrate and luminescence was measured by Luminoscan.
Fig. 3. Iron chelators inhibit basal HIV-1 transcription but not transcription from
CMV or PGK promoters. (a) 293T cells were grown in 96-well plates and
transfected with HIV-1 LTR-LacZ and CMV-EGFP (lane 1) or a TAR deleted
construct of HIV-1 LTR-LacZ (HIV-1 LTRΔTAR) and CMV-EGFP (lane 2) and
treated as indicated with 311 and ICL670. At 24 h the cells were lysed and
analyzed for green fluorescence and for β-galactosidase activity. (b) 293T cells
were transfected with vectors expressing EGFP under the control of
cytomegalovirus (CMV) (lane 1) or cellular phosphoglycerate kinase (PGK)
(lane 2) promoters. At 24 h post transfection, the cells were lysed and GFP
fluorescence was measured on a Luminescence Spectrometer.Treatment with 100 μM ICL670 or 10 μM 311 inhibited
HIV-1 transcription induced by extracellular Tat (Fig. 2a,
lanes 3 and 4). Thus, inhibition of HIV-1 transcription by iron
chelators was not the result of decreased expression of Tat.
We next analyzed the effect of ICL670 and 311 on HIV-1
transcription from HIV-1 genomic construct pNL4-3 Luc in
293T cells. The 293T cells were transfected with pNL4-3 Luc
construct and simultaneously treated with 100 μM ICL670 or
10 μM 311. Treatment with the chelators inhibited HIV-1
transcription as evidenced by decreased luciferase activity (Fig.
2b, lanes 2 and 3).
We next analyzed the effect of chelators on HIV-1 basal
transcription by transiently transfecting 293T cells with HIV-1
LTR-LacZ reporter combined with cytomegalovirus (CMV)-
EGFP vector to normalize transfection. We also used HIV-1
LTR-LacZ in which the TAR-coding sequence was deleted
(HIV-1 LTR ΔTAR (Ammosova et al., 2003)). Treatment
with 10 μM 311 or 100 μM ICL670 inhibited basal HIV-1
transcription from WT or TAR-deleted HIV-1 LTR (Fig. 3a).
To determine whether the chelators exclusively affect the
Fig. 4. Cytotoxicty of iron chelators and their effect on cellular iron. (a) Cellular
cytotoxicity was measured by trypan blue exclusion assay. CEM-GFP cells were
grown in 96-well plates, infected with Ad-Tat and treated with the indicated
concentration of 311 and ICl670. Cell cultures were continued for 24 h and the
cells were counted to determine cell viability by Trypan blue exclusion assay. (b)
Cytotoxicity of iron chelators was measured by lactate dehydrogenase (LDH)
release. CEM-GFP cells or 293T cells were grown in 96-well plates and
treated as indicated with 311, ICL670 or DMSO vehicle for 24 h. Cytotoxicity
was measured as described in the Materials and Methods. Percentage of
cytotoxicity was calculated using the formula [(Absorbance of the treated
samples−Absorbance of control untreated cells) / (Absorbance of high control
−Absorbance of control)]×100. (c) The effect of iron chelators on cellular
ferritin. CEM-GFP cells were grown in 96-well plate and treated as indicated
with 311, ICL670 or ferric ammonium citrate for 24 h. Ferritin concentration was
measured by ELISA as described in Materials and Methods.
Fig. 5. Iron chelators reduce cellular activity of CDK2. (a) CDK2 expression
determined by Western blotting. 293 cells were grown in 100 mm plates and
treated for the indicated time with 100 μMDFO, 10 μM 311 or 100 μM ICL670
(lanes 3–10). The cells were lysed and CDK2 was immunoprecipitated as
described in Materials and Methods. Lane 1, input control. Lane 2, non-specific
immunoprecipitation. Preimmune IgG was used for the immunoprecipitation.
The precipitated CDK2 was resolved on 10% SDS-PAGE and immunoblotted
with antibodies against CDK2. (b) CDK2 activity determined by histone
phoshorylation. CDK2 was precipitated as in (a) and the immunoprecipitated
material was subsequently incubated with histone H1 in the presence of γ-(32P)
ATP (lanes 2–9). Kinase reactions were resolved on 10% SDS-PAGE and
analyzed on Phosphor Imager. Lane 1: non-specific preimmune IgG. Lane 10,
histone H1 phosphorylation with recombinant CDK2/Cyclin E.
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cellular phosphoglycerate kinase (PGK) promoters. Neither
chelator had a significant effect on transcription from the
CMV promoter (Fig. 3b, lane 2). In the case of the PGK
promoter, 311 did not inhibit transcription whereas ICL670
had an inhibitory effect although not as prominent as for HIV-
1 (Fig. 3b, lane 1).
Taken together, our results indicate that iron chelators
potently inhibit Tat-induced and basal HIV-1 transcription, but
not the transcription from the non-relevant CMV promoter or
PGK promoter.Inhibition of HIV-1 transcription by iron chelators is not due to
decreased cellular proliferation or cellular toxicity
Treatment with ICL670 and 311 did not have a significant
effect on proliferation of CEM-GFP cells as determined by
cell counting. Cellular viability determined from data in Fig.
4a remained above 90% for the cells treated with iron
chelators. Cytotoxicity of iron chelators was analyzed using
lactate dehydrogenase (LDH) release as an indicator of cell
membrane damage. Measurement of LDH in the media of
cultures treated with iron chelators showed minimal LDH
release indicating that iron chelators were not toxic at the
concentrations used (Fig. 4b). Analysis of the effect of 311
and ICL670 on HIV-1 transcription and cellular proliferation
in HeLa-MAGI cells infected with Ad-Tat (Supplemental Fig.
2a; Ammosova et al., 2003) showed that ICL670 and 311
decreased cell proliferation by approximately 20% at con-
centrations that inhibited HIV-1 transcription by 50%
(Supplemental Fig. 2b and c). In contrast, the effect of DFO
on cell proliferation was more pronounced (Supplemental Fig.
2d) thus confirming previous observations that DFO decreases
cellular proliferation. To confirm that iron chelators changed
intracellular iron levels, we measure intracellular concentra-
tions of ferritin which reflects the iron status of the cells.
Treatment with 311 reduced ferritin level 4-fold, and ICL670-
Fig. 6. Iron chelators reduce HIV-1 Tat phosphorylated in cultured cells. HeLa
cells were infected with recombinant adenovirus expressing Flag-tagged Tat as
described in Materials and Methods (lanes 2–5). Lane 1, control uninfected
cells. HeLa cells were transfected with siRNAs targeting CDK2 (lane 3) or
treated with 10 μM 311 or 100 μM ICL670. At 48 h post infection cells were
labeled with (32P)-orthophosphate for 2 h with the addition of 1 μM okadaic
acid. Whole cell extracts were prepared and Tat was immunoprecipitated with
anti-Flag monoclonal antibodies, resolved on 15% Tris–Tricine SDS-PAGE and
detected by Phosphor Imager. Phosphor Imager quantification is shown in the
lower panel.
Fig. 7. Iron chelators disrupt association of CDK9 with cyclin T1 and inhibit
phosphorylation of RNAPII. (a) Chelators do not have an effect on expression
of CDK9. 293 cells were treated for 24 h with 10 μM 311 or 100 μM of ICL670.
The cells were lysed were resolved on 10% SDS-PAGE, and immunoblotted
anti-CDK9 antibodies. Lane 1: control untreated cells; lanes 2, 3 and 4: cells
treated with DFO, 311 or ICL670. (b) Chelators inhibit association of CDK9
with cyclin T1. The cell lysates prepared as in (a) were subjected to
immunoprecipitation with anti-cyclin T1 antibody (lanes 3–6). The immuno-
precipitated material was resolved on 10% SDS-PAGE, and immunoblotted
anti-CDK9 antibodies. Lane 1: input control untreated cells; lane 2:
precipitation of untreated cells with non-specific preimmune IgG; lanes 3–6:
immunoprecipitation with anti-cyclin T1 antibodies of lysates from untreated,
DFO, 311 and ICL670 treated cells. The precipitated samples were resolved on
10% SDS-PAGE and immunoblotted with antibodies against CDK9. (c) Che-
lators inhibit phosphorylation of RNAPII. The cell lysates prepared as in (a)
were resolved on 7.5% SDS-PAGE, and immunoblotted with the RNAPII CTD
phospho-Serine 2 specific antibodies. Lane 1: control untreated cells; lanes
2,3 and 4: cells treated with DFO, 311 or ICL670.
328 Z. Debebe et al. / Virology 367 (2007) 324–33310-fold (Fig. 4c, compare lane 1 to lanes 2 and 3). Treatment of
the cells with 100 μM ferric ammonium citrate increased ferritin
concentration 3-fold. These results indicate that treatment with
iron chelators markedly reduced intracellular iron concentration.
When 311 or ICL670were precomplexed with ferric ammonium
citrate, there was no effect on cell proliferation (Supplemental
Fig. 2a and b) and the Fe complexes of 311 or ICL670 did not
affect Tat-induced transcription (Supplemental Fig. 2c).
Together, these results are consistent with the concept that the
effects of iron chelators on HIV-1 transcription are due to the
depletion of intracellular iron and not the consequence of the
increased cellular toxicity.
Iron chelators inhibit CDK2 activity and Tat phosphorylation
in cultured cells
Previously, CDK2 expression was shown to be reduced
upon chelating of intracellular iron by 311 or DFO (Gao and
Richardson, 2001). We measured levels and activity CDK2 in
293 cells treated with 311 (10 μM), ICL670 (100 μM) or DFO
(100 μM) for 24 h and 48 h. Western blot analysis showed that
chelators did not have a significant effect on the protein
expression of CDK2 (Fig. 5a). We further analyzed the effect
of iron chelators on the enzymatic activity of CDK2 using
histone H1, which is a general substrate for a number of
serine/threonine kinases including CDK2. Recombinant
CDK2/Cyclin E efficiently phosphorylated histone H1 (Fig.
5b, lane 10). CDK2 immunoprecipitated from untreated 293
cells lysates by polyclonal antibody to CDK2 also effectively
phosphorylated histone H1 (Fig. 5b, lanes 2 and 6). Treatmentof 293 cells with DFO, 311 or ICL670 dramatically inhibited
phosphorylation of histone H1 by CDK2 (Fig. 5b, lanes 3–5
and lane 7–9).
We recently showed that CDK2 phosphorylates HIV-1 Tat
in cultured cells (Ammosova et al., 2006). Phosphorylation of
Tat was increased in HeLa cells infected with Ad-Tat and
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(Ammosova et al., 2006). To analyze if iron chelators affect
Tat phosphorylation, HeLa cells were infected with Adeno-Tat
and incubated 48 h post infection to allow expression of Tat,
with or without the treatment with iron chelators. As a control,
we also transfected cells with CDK2-directed siRNA that we
previously showed to block Tat phosphorylation (Ammosova
et al., 2006). The cells were pulsed with (32P)-labeled
orthophosphate and treated with okadaic acid. Tat was
immunoprecipitated from cellular lysates, resolved by SDS-
PAGE on 15% Tris–Tricine gel (Schagger et al., 1996) and
detected by Phosphor Imager (Fig. 6, lane 2). Inhibition of
CDK2 by siRNA reduced the level of Tat phosphorylation
(Fig. 6, lane 3). Treatment with 311 or ICL670 also
significantly reduced Tat phosphorylation (Fig. 6, lanes 4–5).
Taken together, these results suggest that iron chelators in-
hibit CDK2 activity in cultured cells and also reduce Tat
phosphorylation.
ICL670 and 311 inhibit association of CDK9 with cyclin T1
and phosphorylation of RNA polymerase II
We next analyzed whether iron chelators have an effect on
the expression of CDK9, a well-established co-factor in Tat-
induced transcription (Wei et al., 1998; Yang et al., 1997; Zhu
et al., 1997). CDK9 expression was analyzed by immuno-
blotting in 293 cells untreated or treated with 100 μM DFO,
10 μM 311 or 100 μM ICL670 for 24 h. The chelators did
not have a significant effect on the protein level of CDK9
(Fig. 7a). Cyclin T1 association with CDK9 is critical for the
kinase activity of CDK9 and for its interaction with HIV-1 Tat
and TAR RNA (Wei et al., 1998). To analyze the association
of CDK9 with cyclin T1, we immunoprecipitated cyclin T1
and analyzed co-precipitation of CDK9 by immunoblotting.
CDK9 was efficiently co-precipitated with cyclin T1 in
untreated 293 cells (Fig. 7b, lane 3). No reduction in co-
precipitation of CDK9 with cyclin T1 was seen in the cells
treated with DFO (Fig. 7b, lane 4). In contrast, in the cells
treated with 311 or ICL670 there was a significant reduction
in CDK9 co-precipitation (Fig. 7b, lanes 5 and 6). To
determine whether chelators reduced the enzymatic activity of
CDK9, we analyzed the level of RNA polymerase II
(RNAPII) phosphorylation in the treated cells using mono-
clonal antibodies that recognize Ser-2 phosphorylated residue
of the RNAPII C-terminal domain (CTD). RNAPII in the
control cells was phosphorylated (Fig. 7c, lane 1). Chelators
311 and ICL670 decreased the level of RNAPII CTD Ser-2
phosphorylation whereas DFO only had a partial effect (Fig.
7c, lanes 2 to 4). Thus, the potent inhibition of HIV-1
transcription by 311 and ICL670 can be explained by a
reduction of enzymatic activity of CDK9, for which RNAPII
is a substrate in vivo.
Discussion
Induction of HIV-1 transcription by HIV-1 Tat requires
interaction of Tat with CDK9/cyclin T1, TAR RNA (Bieniasz etal., 1998; Garber et al., 1998a, 1998b; Wei et al., 1998), and
CDK2/cyclin E (Agbottah et al., 2005; Ammosova et al., 2005a;
Deng et al., 2002; Nekhai et al., 2002). CDK2/cyclin E
regulates G1/S transition (reviewed in Morgan, 1997). Tat
induces HIV-1 transcription in G1 phase of the cell cycle,
whereas HIV-1 transcription in G2 is Tat-independent (Kashan-
chi et al., 2000; Nekhai et al., 2000b). Tat associates with a
protein complex containing CDK2 (Nekhai et al., 2002).
CDK2/cyclin E can phosphorylate RNA polymerase II CTD
(Deng et al., 2002). CDK2/cyclin E associates with HIV-1
transcription elongation complex and phosphorylates Tat in
vitro and in vivo (Agbottah et al., 2005; Ammosova et al., 2006;
Deng et al., 2002). The significance of CDK2 for HIV-1
transcription was verified with the use of Roscovitine and its
analog CYC202 that inhibit CDK2/cyclin E kinase activity and
prevent replication of wild type and resistant HIV-1 mutants in
T-cells, monocytes and PBMCs (Agbottah et al., 2005).
Additionally, inhibition of CDK2 by siRNA inhibits Tat-
induced transcription from HIV-1 promoter and suppresses viral
replication (Ammosova et al., 2005a; Liang et al., 2005). Recent
studies showed that CDK2 knock-out mice are viable (Berthet
et al., 2003) suggesting that CDK2 is dispensable for
proliferation and survival of most cell types. Therefore,
CDK2 may present a novel target for anti-HIV-1 therapeutics.
Based on these reports, deregulation of CDK2 is likely to affect
HIV-1 transcription.
In this study, we examined the effect of iron chelators on
Tat-induced activation of HIV-1 transcription and the effect of
iron chelators on the expression and activity of CDK2 and
CDK9. Using several cell lines containing an integrated HIV-1
promoter or transfected with a reporter under control of HIV-1,
we demonstrated that the iron chelators, ICL670 and 311, led
to significant inhibition of Tat-induced transcription. The
chelators significantly inhibited enzymatic activity of CDK2.
The chelators also significantly inhibited the enzymatic
activity of CDK9 apparently disrupting the interaction of
CDK9 with cyclin T1, without changing the expression level
of CDK9. Our findings are consistent with the possibility that
iron chelators could conceivably be beneficial in antiretroviral
combination therapy.
The mechanism of CDK2 inhibition by iron chelators is
not yet clarified. CDK2 is positively regulated by the binding
of cyclin E (G1/S transition) or cyclin A (S phase transition)
and by CDK7-mediated phosphorylation of Thr160 (Morgan,
1997). Negative regulation of CDK2 includes its association
with p21(CIP1/WAF1) and p27Kip1 inhibitory proteins and
phosphorylation of Tyr15 by Wee1 kinase (Coulonval et al.,
2003). p21 is not likely to be involved in CDK2 inhibition
because iron chelators reduce p21 protein levels through
inhibition of translocation of p21 (CIP1/WAF1) mRNA from
the nucleus to cytosol and induction of ubiquitin-independent
proteasomal degradation of p21 (Fu and Richardson, 2007).
Interestingly, DFO markedly increases p27Kip1 expression
but not p21(CIP1/WAF1) (Yoon et al., 2002). Thus, it is
possible that the marked decrease of CDK2 activity is related
to inhibition of CDK2 caused by increased p27Kip1
expression.
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(Gao and Richardson, 2001), this is the first study showing
that ICL670 reduces the activity of CDK2. ICL670 is an orally
effective iron chelator recently approved for use in humans
(Porter, 2006). In clinical trials, transfusion-dependent beta-
thalassemia patients tolerated doses of up to 80 mg/kg, which
resulted in plasma concentrations reaching 250 μM (Galanello
et al., 2003). At a dose of 40 mg/kg, the concentration of
ICL670 reached 100 μM in plasma (Galanello et al., 2003). In
our study, about 80% of Tat-induced transcription in T cells
was inhibited by 100 μM ICL670, thus indicating that ICL670
can be potentially investigated as an anti-HIV-1 therapeutics.
Our findings that 311 and ICL670 decrease CDK9 activity
by disrupting the interaction of CDK9 with cyclin T1 indicate
that iron chelators may specifically target HIV-1 transcription.
One potential mechanism of inhibition of HIV-1 transcription
is deregulation of HIV-1 Tat phosphorylation by CDK2. Our
unpublished observations indicate that phosphorylated HIV-1
Tat binds more efficiently to protein phosphatase-1 in vitro
(Nekhai, unpublished observation). Because interaction of Tat
with PP1 is critical for the HIV-1 transcription (Ammosova et
al., 2003, 2005b; Nekhai et al., 2007b), deregulation of this
interaction might be inhibitory for HIV-1 transcription.
Another possibility is that CDK2 directly or indirectly
regulates CDK9 activity by controlling the association of
CDK9 with cyclin T1. Interaction between Tat and cyclin T1
requires zinc as well as essential cysteine residues in both
proteins (Garber et al., 1998a, 1998b). Although the chelators
clearly had an effect on intracellular iron which is indicated by
decreased cellular ferritin levels, chelation of zinc might affect
the interaction of Tat with cyclin T and inhibit HIV-1
transcription. That ICL670 inhibited cell proliferation only
slightly, while HIV-1 transcription was potently inhibited
further adds to the attractiveness of considering this agent in
HIV therapeutics. Our findings suggest the need to further
evaluate iron chelators as potential CDK2 and/or CDK9




Recombinant CDK2/cyclin E was expressed and purified as
described (Deng et al., 2002). Histone-H1 was purchased from
Upstate Cell Signaling Solutions (Charlottesville, VA). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was purchased from Sigma-Aldrich Chemical Co. (St Louis,
MO). All other inorganic reagents were purchased from Fisher
Scientific (Fair Lawn, NJ) or Sigma Chemical (St Louis, MO).
Anti-Flag monoclonal antibodies, protein (G) and protein (A)
agarose, and okadaic acid were purchased from Sigma (Atlanta,
GA). All radioactive reagents were purchased from GE Health
Care Life Sciences. Antibodies for CDK2 and CDK9 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies against RNAPII were from Covance Research
Products (Cambridge, MA). 293T cells and 293 cells werepurchased from ATCC (Manassas, VA). Horseradish peroxidase
(HRP)-conjugated F(ab)2 fragment was purchased from Amer-
sham Biosciences (Piscataway, NJ).
Plasmids
The HIV-1 reporter contained HIV-1 LTR (−138 to +82)
followed by a nuclear localization signal (NLS) and the LacZ
reporter gene (courtesy of Dr. Michael Emmerman, Fred
Hutchinson Cancer Institute, Seattle, WA) (Kimpton and
Emerman, 1992). The HIV-1 reporter plasmid without TAR
contained a deletion of +19 to +87 nucleotides of LTR in-
troduced by restriction digestion with BglII (Ammosova et al.,
2003). The CMV-EGFP was cloned into the Adenovirus shuttle
vector. The SIN vector containing the phosphoglycerol kinase
(PGK) promoter followed by EGFP (Brenner andMalech, 2003)
was a gift from Dr. John Tisdale (NIDDK, NIH). An HIV-1
genomic plasmid pNL4-3.Luc.R-E-containing firefly luciferase
gene in place of nef and frame shifts in the Env and Vpr genes
were obtained from the NIH AIDS Research and Reference
Reagent Program (courtesy of Dr. Nathaniel Landau, Aaron
Diamond AIDS Research Center, The Rockefeller University)
(He et al., 1995).
Iron chelator solutions and chelator–Fe(III) complexes
The aroylhydrazone iron chelator, 2-hydroxy-1-naphthylal-
dehyde isonicotinoyl hydrazone (311), is a tridentate ligand with
high affinity for Fe3+ and it was synthesized as previously
described (Richardson and Bernhardt, 1999). The oral iron
chelator 4-[3,5-bis-(hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic
acid (ICL670, deferasirox) which forms a very stable 2:1
complex with Fe3+ was a generous gift from Dr. Anna Suter,
Novartis, Pharma AG, Ltd., Basel, Switzerland. Where
indicated, the chelators were complexed to ferric ammonium
citrate at equimolar concentrations.
Cell culture
293Tand 293 cells were grown andmaintained in Dulbecco’s
Minimal Essential Medium (DMEM) containing 10% fetal
bovine serum (FBS) (Gibco-BRL) and 1% glutamine (Gibco-
BRL). CEM-HIV-1 LTR-GFP cells (CEM-GFP; obtained from
the NIH AIDS Research and Reference Reagent Program,
courtesy of Dr. Jacques Corbeil) were cultured andmaintained in
RPMI Medium 1640 containing 10% FBS, with 1% antibiotic
solution and 500 μg/ml G418 (Invitrogen). HeLa-CD4-LTR-β-
gal cells (MAGI; obtained from the NIH AIDS Research and
Reference Reagent Program, courtesy of Dr. Michael Emerman)
(Kimpton and Emerman, 1992) were cultured and maintained in
DMEM containing 10% fetal bovine serum (FBS) (Gibco-BRL)
and 1% glutamine (Gibco-BRL) with 1% antibiotic solution
(penicillin and streptomycin; Gibco-BRL) and 200 μg/ml G418
and 100 ng/ml Hygromycin B (Invitrogen). The viability of
CEM-GFP cells was determined by trypan blue exclusion assay.
HeLa MAGI cell viability was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
331Z. Debebe et al. / Virology 367 (2007) 324–333dye conversion assay, which has a stable endpoint. If not
indicated, the cell cultures were treated with the chelators for
24 h.
Induction of HIV-1 transcription with Ad-Tat
The E1-deleted recombinant Adeno virus carrying Tat was
generated as previously described (Ammosova et al., 2003).
CEM-GFP cells were infected with MOI 100 Pfu per cell in
a 96-well plate containing 400,000 cells per well. After 24 h
of incubation, the photographs of the cells were taken using
Olympus CKX41 fluorescent microscope with blue filter and
Kodak DC120 digital camera. Then 10 μl aliquots were
removed, supplemented with trypan blue and counted to
determine the cellular viability. The remaining cells were
precipitated by centrifugation, lysed for 20 min at room
temperature in 50 μl of lysis buffer, containing 20 mM
HEPES at pH 7.9, 0.1% NP-40 and 5 mM EDTA transferred
into 150 μl of PBS. The fluorescence was measured with
480 nm excitation and 510 nm emission on Luminescence
Spectrometer LS50B (Perkin-Elmer) equipped with the
robotic 96-well scanner. HeLa-MAGI cells were infected
with MOI 10 Pfu per cell in a 96-well plate containing
10,000 cells per well. After 24 h of culturing, half of the
HeLa cells were incubated with MTT to determine cell
viability and the second half were analyzed for the level of
β-galactosidase expression. To determine the activity of β-
galactosidase, media was removed and the cells were lysed
for 20 min at room temperature in 50 μl of lysis buffer,
containing 20 mM HEPES at pH 7.9, 0.1% NP-40 and
5 mM EDTA. Subsequently, 100 μl of o-nitrophenyl-β-D-
galactopyranoside (ONPG) solution (72 mM Na2 PO4 at pH
7.5, 1 mg/ml ONPG, 12 mM MgCl2, 180 mM 2-
mercaptoethanol) was added and incubated at room tempera-
ture until a yellow color was developed. The reactions were
timed and stopped by addition of 100 μl of 1 M Na2CO3. The
color intensity of the reaction in the 96-well plate was
analyzed using a micro plate reader at a wavelength of 414 nm
(Lab SystemsMultiscanMS). TheMTT reactions were analyzed
at a wavelength of 620 nm.
Induction of HIV-1 transcription with recombinant Tat
HIV-1 Tat was expressed in E. coli using the pGEM2 Tat
bacterial expression vector (obtained from the NIH AIDS Re-
search and Reference Reagent Program, courtesy of Dr. Richard
Gaynor) and purified on Aquapore RP-300 column (Applied
Biosystems, Foster City, CA) by reversed-phase chromatography,
as described. Purified Tatwas dissolved inRPMImedia and added
to CEM-GFP cells at 3 μg/400,000 cells in the presence of 10mM
chloroquine (Frankel and Pabo, 1988). At 24 h incubation
fluorescence was measured as described above.
Luciferase assay
293T cells were grown in 96-well plate and transfected with
pNL4-3.Luc.R-E-plasmid to measure HIV-1 transcription andwith CMV-EGFP to control for the efficiency of transfection. At
48 h posttransfection the cells were washed with PBS 3 times
and then 100 μl of PBS was added to each well. Then 100 μl of
reconstituted luclite buffer (luclite kit, Perkin Elmer) was added
to each well and after 10 min incubation the lysates were
transferred into the white plates (Perkin Elmer) and lumines-
cence was measured on Labsystems Luminoscan RT (Perkin
Elmer).
Immunoblots and kinase assay
Cells were washed with PBS, and whole-cell lysates were
prepared from control untreated and chelator-treated cells using
whole cell lysis buffer (50 mM Tris–HCl, pH 7.5, 0. 5 M NaCl,
1% NP-40, 0.1% SDS) supplemented with protease cocktail
(Sigma). Protein concentration of lysates was determined by
Bradford assay (Bio-Rad) and 50 μg of total protein was
subjected to electrophoresis on 10% SDS-PAGE. The gels were
transferred onto PVDF membrane (Millipore, Allen, TX), and
analyzed for CDK9. The blots were developed and quantified
using ChemiDoc XRS Station (Bio-Rad). CDK2 immunopre-
cipitation was carried out with 100 μg of the cell lysate and
400 ng of anti-CDK2 rabbit polyclonal antibodies combined
with 40 μl of 50% slurry of protein A agarose for 2 h at 4 °C in a
TNN Buffer containing 50 mM Tris–HCl, pH 7.5, 0.15 M
NaCl, and 1% NP-40. The agarose beads were precipitated,
washed with TNN buffer and divided into two parts, and used
for the kinase assay and western blotting. Kinase assay was
performed at 30 °C for 30 min in a kinase assay buffer (50 mM
HEPES–KOH, pH 7.9, 10 mM MgCl2, 6 mM EGTA, 2. 5 mM
DTT) containing 1 μg of histone H1 as a substrate, 200 μMATP
and 5 μCi of [γ-P32]ATP. Recombinant CDK2/cyclin E was
used as a control. Reaction was stopped with SDS-loading
buffer and resolved on 10% PAGE. Dried gel was exposed to
Phosphor Imager screen. In parallel, the immunoprecipitated
CDK2 was resolved on 10% Tris–Glycine SDS-PAGE,
transferred to polyvinylidene fluoride (PVDF) membranes
(Millipore, Allen, TX) and immunoblotted with anti-CDK2
antibodies.
LDH dehydrogenase cytotoxicity assay
Lactate dehydrogenase (LDH) release, used as indicator of
cell membrane damage was measured in the culture medium
using an LDH assay kit (LDH-Cytotoxicity Assay Kit,
BioVision, Mountain View, CA). To measure the cytotoxicity
of the iron chelators, the procedure was followed as described
by the provider. Briefly, the media was collected and mixed with
100 μl of reaction mixture provided by the manufacturer and
incubated for 30 min at room temperature protected from light.
High control was generated by treating cells with 1% Triton X-
100 for 2 h prior to the beginning of the assay. The colorimetric
change was measured with a microtiter reader (Labsystem
Multiskan MS) at 450 nm. Percentage of cytotoxicity was
calculated using the formula [(Absorbance of the treated
samples−Absorbance of control untreated cells) / (Absorbance
of high control−Absorbance of control)]×100.
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CEM-GFP cells were grown in 6-well plates and treated with
the indicated concentrations of iron chelators and ferric
ammonium citrate. After 24 h of treatment cytoplasmic extracts
were prepared as we previously described (Nekhai et al.,
2000a). In brief, the cells were lysed for 10 min at 4 °C in a cell
homogenizing buffer containing 10 mM Tris–HCl (pH 7.5),
6 mM MgCl2, 80 mM KCl, 2 mM DTT, 250 mM Sucrose,
0.1 mM EDTA and 1% Triton. Lysates were span at 10,000 g for
15 min to precipitate nuclear material and organelles. The S-10
cytoplasmic extracts were used to measure ferritin using Spectro
Ferritin Elisa kit (Ramco Laboratories, TX).
Tat phosphorylation in cultured cells
HeLa cells were infected with recombinant Ad-Tat. At
48 h post infection the media was changed for 1 h to a
phosphate-free DMEM media (Life Technologies, Rockville,
MD) containing no serum. Then the media was changed to
phosphate-free DMEM supplemented with 0.5 mCi/ml of
(32P)-orthophosphate and cells were further incubated for 2 h
at 37 °C. About 1 μM okadaic acid (Sigma) was added to
block cellular PPP-phosphatases. Cells were washed with PBS
and lysed in whole cell lysis buffer (50 mMTris–HCl, pH 7.5, 0.
5 M NaCl, 1% NP-40, 0.1% SDS) supplemented with protease
cocktail (Sigma). After 10 min on ice, cellular material was
scraped and then centrifuged at 14,000 rpm, 4 °C for 30min. The
supernatant was recovered and immediately used for immuno-
precipitation. Tat was precipitated with anti-Flag monoclonal
antibodies coupled to protein G agarose for 2 h at 4 °C in a TNN
Buffer containing 50 mM Tris–HCl, pH 7.5, 0.15 M NaCl, and
1% NP-40. The immunoprecipitated Tat was recovered by
heating for 2 min at 100 °C in Tricine SDS-loading buffer,
resolved on 15% Tris–Tricine SDS-PAGE (Schagger et al.,
1996) and transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore, Allen, TX). The membrane was
analyzed with anti-Tat monoclonal antibodies using 3, 3′-
Diaminobenzidine enhancer system (Sigma) and was also
exposed to Phosphor Imager screen (Packard Instruments,
Wellesley, MA). CDK2 expression was inhibited with CDK2-
directed siRNA pool (M-003236-03-005) purchased from
Dharmacon (Dallas, TX). The siRNAs were transfected at
final concentration of 100 nM using Lipofectamin reagent
(Invitrogen) according to the manufacturer’s recommendations.
The siRNAwere incubated with cells for 2 days before cells were
labeled with 32P.
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